Crinetics Pharmaceuticals

Historical price data

Crinetics Pharmaceuticals is building a premier endocrine-focused biopharma company by developing oral small-molecule drugs targeting G-protein coupled receptors (GPCRs). Its lead candidate, paltusotine, is in late-stage development for acromegaly and neuroendocrine tumors, positioning the company for near-term commercialization. The strategy leverages a proprietary platform and deep scientific expertise to address significant unmet needs in endocrinology, a field ripe for innovation.

Proprietary platform for designing selective, oral, nonpeptide small molecules that target peptide-activated G-protein coupled receptors (GPCRs) within the endocrine system.